XENT Intersect ENT Inc

Registration No. 333-263368

Registration No. 333-254034

Registration No. 333-236706

Registration No. 333-229956

Registration No. 333-226591

Registration No. 333-223307

Registration No. 333-216319

Registration No. 333-209713

Registration No. 333-202670

Registration No. 333-197885

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

---

Post-Effective Amendment No. 1

to

FORM S-8 REGISTRATION STATEMENT NO. 333-263368

FORM S-8 REGISTRATION STATEMENT NO. 333-254034

FORM S-8 REGISTRATION STATEMENT NO. 333-236706

FORM S-8 REGISTRATION STATEMENT NO. 333-229956

FORM S-8 REGISTRATION STATEMENT NO. 333-223307

FORM S-8 REGISTRATION STATEMENT NO. 333-216319

FORM S-8 REGISTRATION STATEMENT NO. 333-209713

FORM S-8 REGISTRATION STATEMENT NO. 333-202670

FORM S-8 REGISTRATION STATEMENT NO. 333-197885

UNDER THE SECURITIES ACT OF 1933

 

---

Intersect ENT, Inc.

(Exact name of Registrant as Specified in Its Charter)

---

1555 Adams Drive

Menlo Park, California 94025

(650) 641-2100

(Address of Principal Executive Offices)

---

2014 Equity Incentive Plan

2014 Employee Stock Purchase Plan

(Full title of the plans)

(Name, address and telephone number, including area code, of agent for service)

 

---

Copies to:

(617) 235-4824

 

---

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

---

DEREGISTRATION OF SECURITIES

 

This Post-Effective Amendment relates to the following Registration Statements filed by Intersect ENT, Inc. (the “Registrant” or the “Company”) on Form S-8 (collectively, the “Registration Statements”):

•

Registration Statement No. 333-202670, filed with the SEC on March 11, 2015, relating to the registration of 701,328 shares of Common Stock for issuance under the Company’s 2014 Equity Incentive Plan and 233,776 shares of Common Stock for issuance under the Company’s 2014 Employee Stock Purchase Plan; and

•

Registration Statement No. 333-197885, filed with the SEC on August 6, 2014, relating to the registration of 1,577,667 shares of Common Stock for issuance under the Company’s 2003 Equity Incentive Plan, 656,462 shares of Common Stock for issuance under the Company’s 2013 Equity Incentive Plan, 4,750,008 shares of Common Stock for issuance under the Company’s 2014 Equity Incentive Plan and 496,092 shares of Common Stock for issuance under the Company’s 2014 Employee Stock Purchase Plan.

The Company is filing this Post-Effective Amendment No. 1 to the Registration Statement Nos. 333-263368; 333-254034; 333-236706; 333-229956; 333-226591; 333-223307; 333-216319; 333-209713; 333-202670; 333-197885 to withdraw and remove from registration any and all shares of Common Stock that remain unsold or otherwise unissued under the Registration Statements.

 

On May 13, 2022, pursuant to the Agreement and Plan of Merger, dated as of August 6, 2021 (the “Merger Agreement”), by and among the Company, Medtronic, Inc., a Minnesota corporation (“Parent”), and Project Kraken Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Parent (“Merger Sub”), Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and as a wholly owned subsidiary of Parent.

 

As a result of the consummation of the transactions contemplated by the Merger Agreement, the Registrant has terminated all offerings of its securities pursuant to the Registration Statements. In accordance with an undertaking made by the Registrant in each of the Registration Statements to remove from registration, by means of a post-effective amendment, any securities which remain unsold at the termination of the offering, the Registrant hereby removes and withdraws from registration all securities of the Registrant registered pursuant to the Registration Statements that remain unsold or otherwise unissued as of the date hereof. The Registration Statements are hereby amended, as appropriate, to reflect the deregistration of such securities, and the Registrant hereby terminates the effectiveness of the Registration Statements.

Intersect ENT (NASDAQ:XENT)
Historical Stock Chart
From Nov 2024 to Dec 2024

Intersect ENT (NASDAQ:XENT)
Historical Stock Chart
From Dec 2023 to Dec 2024